Trinity Biotech shares surged nearly 50% premarket after the company secured an order for 9 million units of its WHO-prequalified TrinScreen HIV rapid test. The contract supports deliveries through Q4 2025 and Q1 2026. Trinity also reported a 32% sequential revenue jump in Q3 and a return to positive adjusted EBITDA.